Sheena Jonathan 4
4 · Natera, Inc. · Filed Mar 20, 2026
Research Summary
AI-generated summary of this filing
Natera (NTRA) Co‑Founder & Director Sheena Jonathan Sells Shares
What Happened
- Sheena Jonathan, a director and co‑founder of Natera, sold a total of 4,570 NTRA shares in open‑market transactions on March 18 and March 20, 2026. The individual lots reported: 300 @ $196.27 ($58,880), 956 @ $197.84 ($189,135), 1,814 @ $198.65 ($360,355), and five smaller lots on March 20 (239, 140, 371, 235, 235, 280 shares) at weighted average prices in the ~$198.49–$200.97 range, bringing total proceeds to about $908,300. These were sales (not purchases) and thus are not a direct bullish signal.
Key Details
- Transaction dates: March 18, 2026 and March 20, 2026; Form 4 filed March 20, 2026 (appears timely).
- Total shares sold: 4,570; total proceeds: ≈ $908,300.
- Reported prices include weighted averages covering ranges roughly $196.02 to $201.13 per share (see footnotes F2–F4, F6, F8–F9, F10–F12).
- Sales were effected pursuant to Rule 10b5‑1 trading plans (adopted Dec 11, 2024 and June 7, 2024; footnotes F1 and F5), indicating pre‑arranged trading instructions.
- Shares owned after the transactions are not specified in the supplied details.
Context
- Because these were open‑market sales executed under 10b5‑1 plans, they typically reflect preplanned disposition schedules rather than ad‑hoc insider decisions. Retail investors should view 10b5‑1 sales as routine unless accompanied by other material company news or large, unusual insider activity.
- For a full breakdown of the per‑trade prices within reported weighted ranges, the filer notes (in multiple footnotes) they will provide detailed price/quantity info upon written request.
Insider Transaction Report
Form 4
Natera, Inc.NTRA
Sheena Jonathan
DirectorOther
Transactions
- Sale
Common Stock
[F1][F2]2026-03-18$196.27/sh−300$58,880→ 262,025 total - Sale
Common Stock
[F1][F3]2026-03-18$197.84/sh−956$189,135→ 261,069 total - Sale
Common Stock
[F1][F4]2026-03-18$198.65/sh−1,814$360,355→ 259,255 total - Sale
Common Stock
[F5][F6][F7]2026-03-20$198.85/sh−239$47,526→ 21,543 total(indirect: By Trust) - Sale
Common Stock
[F5][F8][F7]2026-03-20$199.82/sh−140$27,975→ 21,403 total(indirect: By Trust) - Sale
Common Stock
[F5][F9][F7]2026-03-20$200.97/sh−371$74,561→ 21,032 total(indirect: By Trust) - Sale
Common Stock
[F5][F10][F7]2026-03-20$198.49/sh−235$46,644→ 21,547 total(indirect: By Trust) - Sale
Common Stock
[F5][F11][F7]2026-03-20$199.88/sh−235$46,971→ 21,312 total(indirect: By Trust) - Sale
Common Stock
[F5][F12][F7]2026-03-20$200.90/sh−280$56,253→ 21,032 total(indirect: By Trust)
Footnotes (12)
- [F1]The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.
- [F10]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.4100 to $199.0950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.5950 to $200.1800 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F12]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.6650 to $201.1300 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.02 to $196.39 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.42 to $198.09 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.4200 to $198.9050 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.
- [F6]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.4100 to $199.0950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
- [F8]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.5950 to $200.1300 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.6650 to $201.1300 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Tami Chen, Attorney-in-Fact|2026-03-20